News & Events
Insight Genetics today announced that it has added four new team members: David Burg is Associate Director, Business Development; Dan Bailey, MBA, is Senior Associate, New Product Planning; Tyler Nielsen, MBS, is Research Associate III; Lindsay Chatfield is Research Associate I
Insight Genetics featured in Canada’s Annual Report Card on Cancer, “Regulatory Approval and Funding of Precision Medicine in Non-Small Cell Lung Cancer”
Last week, Insight Genetics’ work in the Canadian cancer market was noted in the Cancer Advocacy Coalition of Canada’s Annual Report Card on Cancer. Insight Genetics’ Insight ALK Screen™ was featured in an article in the report, highlighted for its role in enabling precision medicine in cancer care.
Insight Genetics mentioned in Canada’s Annual Report Card on Cancer, “I’ve Been Coughing for a Long Time”
A real-world example of the utility and importance of Insight ALK Screen can be illustrated in the personal account of Vickie Thomas, who shared the story of her battle with lung cancer in “I’ve Been Coughing for a Long Time.”
Insight Genetics presents “ALK: A potential oncogenic driver in triple-negative breast cancer?” at ASCO Annual Meeting.
Insight Genetics, in collaboration with Virginia G. Piper Cancer Center Clinical Trials, Scottsdale Healthcare, Boston Baskin Cancer Foundation, Baptist Cancer Center, and University of Colorado Cancer Center, presented a poster at the American Society of Clinical Oncology’s 2013 Annual Meeting in Chicago that describes the presence of full-length ALK activity in triple-negative breast cancer.
“Insight Genetics is dedicated to providing the highest quality services to our customers and partners,” said Eric Dahlhauser, Chairman and CEO of Insight Genetics. “This certification demonstrates the rigorous quality standards we uphold in our lab and underscores our commitment to physicians caring for those with cancer and to drug developers advancing treatments available to these patients.”